Polypharmacy and medicine regimens in older adults in residential aged care

Amy Page(The University of Western Australia), Christopher Etherton‐Beer(The University of Western Australia), Vasi Naganathan(The University of Sydney), Andrew J. McLachlan(The University of Sydney), Dee Mangin(University of Otago), Richard I. Lindley(Westmead Hospital), Sarah N. Hilmer(Northern Sydney Local Health District), Kathleen N. Potter(University of Southampton), Tracy Coman(Griffith University)

Archives of Gerontology and Geriatrics

November 4, 2022

10.1016/j.archger.2022.104849

Cited by 41

Related Papers

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration

|The Lancet Neurology|2013|5.4k

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

|The Lancet|2014|2.7k

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

|The Lancet|2012|1.2k

Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes

|Journal of Clinical Epidemiology|2012|1.2k

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

|The Lancet|2012|1k